George K. Ng - 30 Jun 2026 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: PCSA
Reported as of: 30 Jun 2026
Net transaction value: +$5,900
SEC form: 4
Accepted by SEC: 01 Jul 2026, 16:19:02 UTC
Prior SEC filing: 16 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ George Ng, by John J. Wolfel, as Attorney-in-Fact

Key filing fact

George K. Ng filed Form 4 for Processa Pharmaceuticals, Inc. (PCSA) on 01 Jul 2026.

Key facts

This page summarizes George K. Ng's Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Jul 2026, 16:19.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CIK 0001638744 Primary reporting owner

Relationship: Chief Executive Officer, Director
Address: C/O PROCESSA PHARMACEUTICALS, INC., 601 21ST STREET SUITE 300, VERO BEACH
Signature: /s/ George Ng, by John J. Wolfel, as Attorney-in-Fact
Signature date: 01 Jul 2026

Shares, units, or other non-derivative securities reported in this filing.

PCSA transaction

Purchase

PCSA holding

No transaction description listed

PCSA holding

No transaction description listed

^* marks a reported price that did not pass the local price check.